Investigation of the association between Rho/Rho-kinase gene polymorphisms and systemic sclerosis

Rheumatology International

Volumn 36, Issue 3, 2016, Pages 421-427

  Pehlivan, Yavuz ^a   Yolbas, Servet ^b   Cetin, Gozde Yıldırım ^b   Alibaz Oner, Fatma ^b   Cagatay, Yonca ^b   Yilmaz, Neslihan ^b   Oztuzcu, Serdar ^b   Donmez, Salim ^b   Ozgen, Metin ^b   Koca, Suleyman Serdar ^b   Pamuk, Omer Nuri ^b   Sayarlıoglu, Mehmet ^b   Kisacik, Bunyamin ^b   Direskeneli, Haner ^b   Demiryurek, Abdullah Tuncay ^b   Onat, Ahmet Mesut ^b  

^a ULUDAG UNIVERSITY   (Turkey)

^b Department of Rheumatology ^*  (Turkey)

Author keywords

Early diagnosis; Pathogenesis; Rho Rho kinase; Systemic sclerosis

Indexed keywords

PROTEIN; RHO FACTOR; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; RHOC PROTEIN; ROCK 2 PROTEIN; ROCK1 PROTEIN; UNCLASSIFIED DRUG; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHOA PROTEIN, HUMAN; RHOC PROTEIN, HUMAN; ROCK1 PROTEIN, HUMAN; ROCK2 PROTEIN, HUMAN;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS; CASE CONTROL STUDY; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MULTICENTER STUDY; PHENOTYPE; RISK FACTOR; SCLERODERMA, SYSTEMIC; SINGLE NUCLEOTIDE POLYMORPHISM; TURKEY;

ADULT; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RHO GTP-BINDING PROTEINS; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; RISK FACTORS; SCLERODERMA, SYSTEMIC; TURKEY;

EID: 84958603660     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-015-3400-4     Document Type: Article

References (28)

1. Romano E, Manetti M, Guiducci S, Ceccarelli C, Allanore Y, Matucci-Cerinic M (2011) The genetics of systemic sclerosis: an update. Clin Exp Rheumatol 29(2 Suppl 65):75–86
2. Haudek SB, Gupta D, Dewald O, Schwartz RJ, Wei L, Trial J et al (2009) Rho kinase-1 mediates cardiac fibrosis by regulating fibroblast precursor cell differentiation. Cardiovasc Res 83:511–518
3. Sun GP, Kohno M, Guo P, Nagai Y, Miyata K, Fan YY et al (2006) Involvements of Rho-kinase and TGF-beta pathways in aldosterone-induced renal injury. J Am Soc Nephrol 17:2193–2201
4. Allahdadi KJ, Hannan JL, Tostes RC, Webb RC (2010) Endothelin-1 induces contraction of female rat internal pudendal and clitoral arteries through ETA receptor and Rho-kinase activation. J Sex Med 7:2096–2103
5. Tran L, Kompa AR, Kemp W, Phrommintikul A, Wang BH, Krum H (2010) Chronic urotensin-II infusion induces diastolic dysfunction and enhances collagen production in rats. Am J Physiol Heart Circ Physiol 298:H608–H613
6. Sunderkötter C, Riemekasten G (2006) Pathophysiology and clinical consequences of Raynaud’s phenomenon related to systemic sclerosis. Rheumatology (Oxford) 45(Suppl 3):iii33-5
7. Akhmetshina A, Dees C, Pileckyte M, Szucs G, Spriewald BM, Zwerina J et al (2008) Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts. Arthritis Rheum 58:2553–2564
8. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590
9. Pehlivan Y, Gogebakan B, Oztuzcu S, Ozgen M, Cetin GY, Bayraktar R et al (2011) Association between Thr21Met and Ser89Asn polymorphisms of the urotensin II gene and systemic sclerosis. J Rheuomatol 39:106–111
10. Yamane K, Kashiwagi H, Suzuki N, Miyauchi T, Yanagisawa M, Goto K et al (1991) Elevated plasma levels of endothelin-1 in systemic sclerosis. Arthritis Rheum 34:243–244
11. Kahaleh MB (1991) Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action. Arthritis Rheum 34:978–983
12. Franco-Cereceda A, Holm P (1998) Selective or nonselective endothelin antagonists in porcine hypoxic pulmonary hypertension? J Cardiovasc Pharmacol 31:S447–S452
13. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF et al (2001) Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358:1119–1123
14. Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E et al (2004) Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50:3985–3993
15. Park SH, Saleh D, Giaid A, Michel RP (1997) Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respir Crit Care Med 156:600–608
16. Maguire JJ, Kuc RE, Davenport AP (2000) Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br J Pharmacol 131:441–446
17. Pehlivan Y, Onat AM, Comez G, Babacan T (2011) Urotensin-II in systemic sclerosis: a new peptide in pathogenesis. Clin Rheumatol 30:837–842
18. Onat AM, Pehlivan Y, Turkbeyler IH, Demir T, Kaplan DS, Ceribasi AO et al (2013) Urotensin inhibition with palosuran could be a promising alternative in pulmonary arterial hypertension. Inflammation 36:405–412
19. Demir T, Turkbeyler I, Kaplan DS, Pehlivan Y, Orkmez M, Tutar E et al (2013) Effectiveness of palosuran in bleomycin-induced experimental scleroderma. Inflammation 36:75–79
20. Onat AM, Turkbeyler IH, Pehlivan Y, Demir T, Kaplan DS, Taysi S et al (2012) The efficiency of a urotensin II antagonist in an experimental lung fibrosis model. Inflammation 35:1138–1143
21. Lin Y, Matsumura K, Tsuchihashi T, Fukuhara M, Fujii K, Iida M (2004) Role of ERK and Rho kinase pathways in central pressor action of urotensin II. J Hypertens 22:983–988
22. Sappino AP, Masouyé I, Saurat JH, Gabbiani G (1990) Smooth muscle differentiation in scleroderma fibroblastic cells. Am J Pathol 137:585–591
23. Restrepo JF, Guzmán R, Rodríguez G, Iglesias A (2003) Expression of transforming growth factor-beta and platelet-derived growth factor in linear scleroderma. Biomedica 23:408–415
24. Ichiki Y, Smith E, LeRoy EC, Trojanowska M (1995) Different effects of basic fibroblast growth factor and transforming growth factor-beta on the two platelet-derived growth factor receptors’ expression in scleroderma and healthy human dermal fibroblasts. J Investig Dermatol 104:124–127
25. Kitano K, Usui S, Ootsuji H, Takashima S, Kobayashi D, Murai H et al (2014) Rho-kinase activation in leukocytes plays a pivotal role in myocardial ischemia/reperfusion injury. PLoS One 9:e92242
26. Hattori T, Shimokawa H, Higashi M, Hiroki J, Mukai Y, Tsutsui H et al (2004) Long-term inhibition of Rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice. Circulation 109:2234–2239
27. Sun XZ, Tian XY, Wang DW, Li J (2014) Effects of fasudil on hypoxic pulmonary hypertension and pulmonary vascular remodeling in rats. Eur Rev Med Pharmacol Sci 18:959–964
28. Fava A, Wung PK, Wigley FM, Hummers LK, Daya NR, Ghazarian SR et al (2012) Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud’s phenomenon. Arthritis Care Res (Hoboken) 64:925–929